---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Specific populations questions"
description: "Specific populations questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can DATROWAY be used during pregnancy or breastfeeding? How long is contraception needed after DATROWAY? Does DATROWAY affect fertility? Does DATROWAY require dose adjustment for kidney or liver impairment? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Specific populations questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## Specific populations

<a id="datroway-pregnancy-lactation"></a>

### Can DATROWAY be used during pregnancy or breastfeeding?

> “Pregnancy: Based on its mechanism of action, DATROWAY can cause embryo-fetal harm when administered to a pregnant woman because the topoisomerase inhibitor component of DATROWAY, DXd, is genotoxic and affects actively dividing cells. There are no available data on the use of DATROWAY in pregnant women to inform a drug-associated risk. Advise patients of the potential risks to a fetus.
> Lactation: There are no data regarding the presence of datopotamab deruxtecan-dlnk or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with DATROWAY and for 1 month after the last dose.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Pregnancy%3A%20Based%20on%20its%20mechanism,month%20after%20the%20last%20dose.)

<a id="datroway-contraception"></a>

### How long is contraception needed after DATROWAY?

> “Females and Males of Reproductive Potential: Pregnancy Testing: Verify pregnancy status of females of reproductive potential prior to initiation of DATROWAY. Contraception: Females: Advise females of reproductive potential to use effective contraception during treatment with DATROWAY and for 7 months after the last dose. Males: Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with DATROWAY and for 4 months after the last dose.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Females%20and%20Males%20of%20Reproductive,4%20months%20after%20the%20last%20dose.)

<a id="datroway-fertility"></a>

### Does DATROWAY affect fertility?

> “Infertility: Based on findings in animal toxicity studies, DATROWAY may impair male and female reproductive function and fertility. The effects on reproductive organs in animals were irreversible.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Infertility%3A%20Based%20on%20findings%20in,organs%20in%20animals%20were%20irreversible.)

<a id="datroway-renal-hepatic"></a>

### Does DATROWAY require dose adjustment for kidney or liver impairment?

> “Renal Impairment: Monitor patients with renal impairment for increased adverse reactions, including respiratory reactions. A higher incidence of ILD/pneumonitis has been observed in patients with creatinine clearance (CLcr) 30 to <90 mL /min (estimated by Cockcroft Gault). No dosage adjustment is recommended in patients with CLcr 30 to <90 mL/min. The pharmacokinetics of datopotamab deruxtecan-dlnk or DXd in patients with CLcr <30 mL/min is unknown.
> Hepatic Impairment: Monitor patients with moderate hepatic impairment (total bilirubin >1.5 to 3 times ULN and any AST) for increased adverse reactions. Limited data are available in patients with moderate hepatic impairment. No dosage adjustment is recommended in patients with mild hepatic impairment (total bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST). The recommended dosage of DATROWAY has not been established for patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST).”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Renal%20Impairment%3A%20Monitor%20patients%20with,%3E3%20times%20ULN%20and%20any%20AST%29.)

<a id="datroway-geriatric-use"></a>

### Is DATROWAY safe for patients 65 and older?

> “Geriatric Use: Of the 841 patients with breast cancer in TROPION-Breast01, TROPION-Breast02, TROPION-PanTumor01, and TROPION-PanTumor02 treated with DATROWAY 6 mg/kg, 23% were ≥65 years of age and 4.5% were ≥75 years of age. Grade ≥3 and serious adverse reactions were more common in patients ≥65 years (45% and 22%, respectively) compared to patients <65 years (38% and 16%, respectively). No other meaningful differences in efficacy and safety were observed between patients ≥65 years of age versus younger patients.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Geriatric%20Use%3A%20Of%20the%20841,of%20age%20versus%20younger%20patients.)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
